About Court Report: Each week we will report briefly on recently filed biotech and pharma cases.
Allergan, Inc. v. Apotex Inc et al.
1:13-cv-00016; filed January 8, 2013 in the Middle District of North Carolina
• Plaintiff: Allergan, Inc.
• Defendants: Apotex Inc.; Apotex Corp.; Sandoz, Inc.; Hi-Tech Pharmacal Co., Inc.; Watson Pharmaceuticals, Inc.; Watson Laboratories, Inc.; Watson Pharma, Inc.
Infringement of U.S. Patent No. 8,263,054 ("Method of Enhancing Hair Growth," issued September 11, 2012) based on defendants' ANDA to manufacture a generic version of Allergan's Latisse® (bimatoprost topical solution/drops, 0.03%, used to treat inadequate or not enough eye lashes). View the complaint here.
Xenetic Biosciences plc v. Kappos
1:13-cv-00022; filed January 7, 2013 in the Eastern District of Virginia
Review and correction of the patent term adjustment calculation made by the U.S. Patent and Trademark Office for U.S. Patent No. 8,217,154 ("Activated Sialic Acid Derivatives for Protein Derivatisation and Conjugation," issued July 10, 2012). View the complaint here.
Novartis Pharmaceuticals Corp. et al. v. Alvogen Pine Brook Inc. et al.
1:13-cv-00052; filed January 4, 2013 in the District Court of Delaware
• Plaintiffs: Novartis Pharmaceuticals Corp.; Novartis AG; Novartis Pharma AG; Novartis International Pharmaceutical Ltd.; LTS Lohmann Therapie-Systeme AG
• Defendants: Alvogen Pine Brook Inc.; Alvogen Group Inc.
Infringement of U.S. Patent Nos. 6,316,023 ("TTS Containing an Antioxidant," issued November 13, 2001) and 6,335,031 (same title, issued January 1, 2002) following a Paragraph IV certification as part of Alvogen's filing of an ANDA to manufacture a generic version of Novartis' Exelon® Patch (rivastigmine tartrate, used to treat mild to moderate dementia of the Alzheimer's type, and mild to moderate dementia associated with Parkinson's disease). View the complaint here.
Genetic Technologies Ltd. v. General Genetics Corp.
1:13-cv-00055; filed January 4, 2013 in the District Court of Delaware
Infringement of U.S. Patent No. 5,612,179 ("Intron Sequence Analysis Method for Detection of Adjacent Locus Alleles as Haplotypes," issued March 18, 1997) based on Natera's manufacture, use, sale, and offer for sale of paternity, predisposition, and forensics testing. View the complaint here.
Astrazeneca AB et al. v. Dr. Reddy's Laboratories, Inc. et al.
3:13-cv-00091; filed January 4, 2013 in the District Court of New Jersey
• Plaintiffs: Astrazeneca AB; Astrazeneca LP; KBI-E Inc; Pozen Inc.
• Defendants: Dr. Reddy's Laboratories, Inc.; Dr. Reddy's Laboratories, Ltd.
Infringement of U.S. Patent Nos. 5,714,504 ("Compositions," issued February 3, 1988), 6,369,085 ("Form of S-omeprazole," issued April 9, 2002), 7,411,070 ("same title," issued August 12 ,2008), 7,745,466 (same title, issued June 29, 2010), and 6,926,907 ("Pharmaceutical Compositions for the Coordinated Delivery of NSAIDs," issued August 9, 2005) following a Paragraph IV certification as part of Dr. Reddy's filing of an ANDA to manufacture a generic version of AstraZeneca's Vimovo® (naproxen and esomeprazole magnesium, used to relieve the signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, and to decrease the risk of stomach (gastric) ulcers in patients at risk of developing stomach ulcers from treatment with non-steroidal anti-inflammatory drugs (NSAIDs)). View the complaint here.
Noven Pharmaceuticals, Inc. v. Kappos
1:13-cv-00017; filed January 4, 2013 in the Eastern District of Virginia
Review and correction of the patent term adjustment calculation made by the U.S. Patent and Trademark Office for U.S. Patent No. 8,216,606 ("Dermal Composition for Controlling Drug Flux Comprising Two Acrylic Adhesive Polymers Having Different Functionalities and Different Solubility Parameters," issued July 10, 2012). View the complaint here.
Celldex Therapeutics Inc. v. Kappos
1:13-cv-00018; filed January 4, 2013 in the Eastern District of Virginia
Review and correction of the patent term adjustment calculation made by the U.S. Patent and Trademark Office for U.S. Patent No. 8,236,318 ("Antibodies That Bind Human Dendritic and Epithelial Cell 205 (DEC-205)," issued August 7, 2012). View the complaint here.
Transcept Pharmaceuticals, Inc. v. Kappos
1:13-cv-00019; filed January 4, 2013 in the Eastern District of Virginia
Review and correction of the patent term adjustment calculation made by the U.S. Patent and Trademark Office for U.S. Patent No. 8,242,131 ("Methods of Treating Middle-of-the-Night Insomnia," issued August 14, 2012). View the complaint here.